Navigation Links
Inverness Medical Innovations Announces First Quarter 2008 Results
Date:4/24/2008

WALTHAM, Mass., April 24 /PRNewswire-FirstCall/ -- Inverness Medical Innovations, Inc. (Amex: IMA), a global leader in rapid point-of-care diagnostic products, today announced its financial results for the quarter ended March 31, 2008.

In the first quarter of 2008, the Company recorded net revenue of $372.2 million compared to net revenue of $159.0 million in the first quarter of 2007. The revenue increase was primarily due to increased product and service revenue in our Professional Diagnostics segment which grew from $83.8 million in the first quarter of 2007 to $259.6 million in 2008, principally as a result of businesses acquired which contributed $152.4 million of the increased product and service revenue. Also contributing to the net revenue increase was product and service revenue provided by our newly formed Health Management segment totaling $45.2 million in the first quarter of 2008. In addition, total royalty and license revenue grew from $5.2 million in the first quarter of 2007 to $10.9 million in 2008, principally as a result of businesses acquired which contributed $4.4 million of the increased royalty and license revenue. As a result of the formation of our Consumer Diagnostics joint venture with The Procter & Gamble Company, we no longer consolidate the third party revenues earned on sales of consumer products sold through the joint venture and instead recognized product sales to the joint venture of $28.9 million in the first quarter of 2008 compared to pre-joint venture formation revenues of $49.9 million in the first quarter of 2007. Despite the $21.0 million of decreased revenues included in our consolidated results, underlying Consumer Diagnostics revenues recorded by the joint venture increased to $54.7 millio
'/>"/>

SOURCE Inverness Medical Innovations, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
2. Inverness - Chemogen Establish Exclusive License for TB Antibodies
3. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
4. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
7. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
8. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
9. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
10. Inverness Medical Innovations Announces Fourth Quarter 2007 Results
11. Inverness Medical Innovations to Participate at Bank of America 2008 Smid Cap Conference on March 26, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... 2015  The Diabetes Research Institute (DRI), a ... Miller School of Medicine, announced today that the ... for the first time a novel transplant technique ... approved Phase I/II study builds upon decades of ... important first step toward the development of the ...
(Date:8/26/2015)... , August 26, 2015 After litigating ... Europlasma NV relating to P2i United States ... their dispute in the United States ... the part of either party. As a result of the ... of California dismissed the case without ...
(Date:8/25/2015)... ... August 25, 2015 , ... ... tissue lesions are cancerous is described by University of Illinois researchers in the ... optics and photonics. , In “ Breast cancer diagnosis using spatial light interference ...
Breaking Biology Technology:Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4P2i Settles United States Litigation 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4
... -Now for Exclusion of Venous Thromboembolism-, LEXINGTON, ... that the US Food and Drug Administration (FDA) ... for the HemosIL D-Dimer,assay to exclude venous thromboembolism ... and pulmonary embolism (PE), when used in,conjunction with ...
... Performance - Net Profit Up 16.8% at Constant Exchange Rates - Essilor Launches a Share Buyback Program ... the six months,ended June 30, 2008., EUR millions First-half 2008 ... ... at constant ...
... UK,s National Physical Laboratory (NPL) to survey nanotechnology capabilities ... to identify the next generation of nano and smart ... , "Advances in nanotechnology are crucial to Europe,s space ... nanomaterials group at NPL, who will be the principal ...
Cached Biology Technology:Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay 2Essilor's First-Half 2008 Results 2Essilor's First-Half 2008 Results 3Essilor's First-Half 2008 Results 4Essilor's First-Half 2008 Results 5Essilor's First-Half 2008 Results 6Essilor's First-Half 2008 Results 7Essilor's First-Half 2008 Results 8
(Date:8/17/2015)...  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... 2015. The new marketing campaign is being spearheaded by ... Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... retail driven marketing and brand awareness and has a ...
(Date:8/11/2015)... 11, 2015 Today, ZUK announced its Android ... well as expected revenues in 2015 that relate to sales of ... guidance of approximately 2,200 MSEK for 2015. Jörgen Lantto, ... prominent smartphone manufacturer in China ... selected FPC1 155 for Z1 ...
(Date:8/6/2015)... 6, 2015 Synaptics Inc. (NASDAQ: ... solutions, today announced collaboration with Microsoft on biometric ... Microsoft leveraged Synaptics, deep expertise in human interface ... Through stringent testing, Synaptics, advanced image ... Microsoft,s Precision TouchPad (PTP) specification empowering OEMs with ...
Breaking Biology News(10 mins):NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... latest American Chemical Society (ACS) Weekly PressPac from the ... 34 peer-reviewed journals and Chemical & Engineering News.,Please credit ... the source for this information. PressPac Archive: ... 1 FOR IMMEDIATE RELEASE, Solving the mystery of what ...
... (April 12, 2009) In certain respects, cells are ... have lots of components, but they also have lots ... are studied in aggregate (conservatives, liberals, atheists, evangelicals), they ... looked at one person at a time, individuals often ...
... a result of exposure to ionizing radiation, they must make ... for death, a process called apoptosis. It,s a ... involving what might be described metaphorically as a network of ... the cell nucleus. In intricate ways, cells orchestrate a ...
Cached Biology News:American Chemical Society Weekly PressPac -- April 8, 2009 2American Chemical Society Weekly PressPac -- April 8, 2009 3American Chemical Society Weekly PressPac -- April 8, 2009 4American Chemical Society Weekly PressPac -- April 8, 2009 5American Chemical Society Weekly PressPac -- April 8, 2009 6American Chemical Society Weekly PressPac -- April 8, 2009 7American Chemical Society Weekly PressPac -- April 8, 2009 8American Chemical Society Weekly PressPac -- April 8, 2009 9American Chemical Society Weekly PressPac -- April 8, 2009 10American Chemical Society Weekly PressPac -- April 8, 2009 11For cancer cells, genetics alone is poor indicator for drug response 2For cancer cells, genetics alone is poor indicator for drug response 3CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 2CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 3CSHL-led team identifies key decision-point at which cells with broken DNA repair themselves or die 4
MagSi monodispers, magnetic silica particles with modified surface for SO3 coupling chemistry....
Recognizes a full-length CLC-2 voltage-gated Cl- protein and not with other known proteins tested so far....
Monoclonal Anti-Gα o purified immunoglobulin buffered aqueous solution Solution in phosphate buffered saline pH 7.4, containing 0.08% sodium azide. partially purified bovine brain Gα O ...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: